Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Part of paid clinical trials in Columbus, Ohio.

Sponsor
David O'Malley
Study ID
NCT00513786
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
  • Paclitaxel — DRUG
    175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
  • bevacizumab — DRUG
    15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.

Study Details

Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.

Key Dates

First listed
Aug 9, 2007
Start date
Aug 1, 2007
Status verified
Mar 2025
Primary completion
Jan 3, 2017
Completion
Jan 3, 2017

Study Design

Enrollment
38 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: carboplatin/paclitaxel with bevacizumab
    A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.

Primary Outcome Measure

Evaluate Patients With Progression Free Survival (PFS) [ Time Frame: up to 57 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Ohio State University-Division of Gyn OncologyColumbusOhio43210-

Find similar trials in Columbus, OH

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
The Ohio State University-Division of Gyn Oncology· Columbus, OH

Related Studies